A5031524718- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Hemoglobinopathies and Related Disorders
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Iron Metabolism and Disorders
- COVID-19 Clinical Research Studies
- T-cell and Retrovirus Studies
- Phytochemical compounds biological activities
- Acute Myeloid Leukemia Research
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Hematological disorders and diagnostics
- HIV/AIDS drug development and treatment
- Venous Thromboembolism Diagnosis and Management
- Neurological and metabolic disorders
- Acute Lymphoblastic Leukemia research
- Ovarian cancer diagnosis and treatment
- Chronic Myeloid Leukemia Treatments
- Erythrocyte Function and Pathophysiology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Synthesis of Tetrazole Derivatives
Azienda Sanitaria Unità Locale di Reggio Emilia
2020-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2025
Santa Maria Nuova Hospital
2021
University of Modena and Reggio Emilia
2011-2020
Fondazione Gimema Onlus
2020
Azienda Ospedaliera S.Maria
2015
University of Rome Tor Vergata
2008-2009
Policlinico Tor Vergata
2008-2009
St. Eugenio Hospital
2008
Sapienza University of Rome
2006
Purpose Despite the identification of several baseline prognostic indicators, outcome patients with acute myeloid leukemia (AML) is generally heterogeneous. The effects autologous (AuSCT) or allogeneic stem-cell transplantation (SCT) are still under evaluation. Minimal residual disease (MRD) states may be essential for assigning to therapy-dependent risk categories. Patients and Methods By multiparametric flow cytometry, we assessed levels MRD in 142 AML who achieved complete remission after...
Not available.
Summary Novel treatments for multiple myeloma ( MM ) have shown promising results in clinical trials, but the advantage unselected patients is still unclear. In order to evaluate whether novel therapies impact survival of patients, we performed a population‐based analysis on data collected by M odena C ancer R egistry from 1989 2009. The evaluated 1206 newly diagnosed years 1988–96 (conventional therapy), 1997–05 (high dose melphalan and autologous transplant), 2006–09 (novel agents era)....
ABSTRACT Relapsed/refractory multiple myeloma (RRMM) research on the impact of +1q abnormalities in real‐world settings is limited. This study evaluated prognostic and predictive significance 1q gain [gain(1q)] amplification [ampl(1q)] 635 RRMM patients treated with daratumumab‐, elotuzumab‐, carfilzomib‐based triplet regimens. Patients had lower deep response rates [≥ CR: 9.4% for gain(1q), 11.6% ampl(1q)] versus 20.2% +1q‐negative patients. Multivariable ordinal logistic analysis showed...
Carfilzomib-lenalidomide-dexamethasone (KRd) has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM). We conducted a retrospective analysis 197 RRMM patients (pts) between January 2016 and March 2018 in six Italian hematologic centers, with aim to evaluate efficacy safety KRd real-life. At initiation 27% carried high risk cytogenetic abnormalities (HRCA) [del17p and/or t(4;14) t(14;16)], median number prior lines therapy was 2 (1-8), nearly all pts (96%) received...
Abstract We conducted a population‐based study to establish the outcome of T‐cell lymphoma (TCL) patients failing systemic first‐line therapy. All TCL therapy in province Modena were identified from Cancer Registry between 1997 and 2010. A total 53 analysed. Regarding type failure, 18 relapsed, 35 progressed during first treatment. Among relapsed patients, median time date response relapse after treatment was 6.2 months (range 1.87–102). (34%) died before receiving salvage treatment, 21...
Sickle cell disease (SCD) is a hereditary blood disorder characterized by abnormal hemoglobin, leading sickle shape of red cells. It has several vascular complications and the cerebrovascular ones are among most frequent severe both in children adults. This review summarizes main neurovascular manifestations SCD, including acute stroke, silent cerebral infarction, large vessel diseases (moyamoya arteriopathy aneurysms) brain bleeding. Both epidemiology, pathophysiology treatment issues...
This article describes the case of a SARS-CoV-2 infection in an 18-year old female Nigerian homozygous sickle cell disease (SCD) patient with expression rare blood group phenotype. The is first-born daughter two trait (SCT) carriers who have settled Italy from Nigeria. On March 6, 2020, self-presented to emergency department (ED) Arcispedale Santa Maria Nuova (ASMN) Reggio Emilia for high grade fever (body temperature > 39°C) and headache persisting past 24 h. Upon physical examination, had...
Sickle cell disease (SCD) is a hereditary blood disorder characterized by abnormal hemoglobin, leading to the sickle shape of red cells. It has several vascular complications and cerebrovascular ones are among most frequent severe both in children adults. This review summarizes main neurovascular manifestations SCD, including acute stroke, silent cerebral infarction, large-vessel diseases (moyamoya arteriopathy aneurysms), brain bleeding. Both epidemiology, pathophysiology, treatment issues...